Condensed Consolidated Statements of Operations (Unaudited) - USD ($) shares in Thousands, $ in Thousands	3 Months Ended		6 Months Ended
	Jun. 30, 2025	Jun. 30, 2024	Jun. 30, 2025	Jun. 30, 2024
Income Statement [Abstract]
Contract revenue	$ 0	$ 0	$ 172	$ 0
Operating expenses
Research and development	5,505	6,115	12,075	13,700
General and administrative	5,000	6,409	10,615	12,857
Total operating expenses	10,505	12,524	22,690	26,557
Loss from operations	(10,505)	(12,524)	(22,518)	(26,557)
Other income (expense), net
Interest income and other, net	158	439	375	988
Interest expense and other, net	(877)	(1,276)	(1,819)	(2,571)
Net loss	(11,224)	(13,361)	(23,962)	(28,140)
Net loss attributable to non-controlling interest	(4,532)	(6,556)	(10,006)	(13,852)
Net loss attributable to Rani Therapeutics Holdings, Inc.	$ (6,692)	$ (6,805)	$ (13,956)	$ (14,288)
Net loss per Class A common share attributable to Rani Therapeutics Holdings, Inc.-Basic	$ (0.18)	$ (0.26)	$ (0.4)	$ (0.55)
Net loss per Class A common share attributable to Rani Therapeutics Holding, Inc., diluted	$ (0.18)	$ (0.26)	$ (0.4)	$ (0.55)
Weighted-average share outstanding basic	36,542	26,324	34,999	26,179
Weighted-average share outstanding diluted	36,542	26,324	34,999	26,179